However, important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these medications may be needed) Not recommended in severe gastrointestinal disease, including severe gastroparesis Risk of diabetic retinopathy complications, particularly in patients with pre-existing retinopathy Pancreatitis risk requiring immediate discontinuation if suspected Not recommended during pregnancy or breastfeeding Not sure where to start
Nelson LD, Temkin NR, Dikmen S, Barber J, Giacino JT, Yuh E, et al
Semaglutide weight loss works by increasing the amount of insulin produced by the pancreas and decreasing the amount of glucagon produced by the liver
Todays milestone expands the strong clinical profile of Wegovy that includes multiple indications that no other GLP-1 for weight loss can claim. As with other drugs in the same class, Wegovy HD comes with a familiar list of potential side effects including nausea, vomiting, constipation, fatigue, dizziness, headache, sensitivity to touch and hair loss